Increased expression of collagen XVIII and its prognostic value in nonsmall cell lung carcinoma

被引:20
作者
Chang, H
Iizasa, T
Shibuya, K
Iyoda, A
Suzuki, M
Moriya, Y
Liu, TL
Hiwasa, T
Hiroshima, K
Fujisawa, T [1 ]
机构
[1] Chiba Univ, Grad Sch Med, Dept Thorac Surg, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan
[2] Chiba Univ, Grad Sch Med, Dept Biochem & Genet, Chuo Ku, Chiba 2608670, Japan
[3] Chiba Univ, Grad Sch Med, Dept Basic Pathol, Chiba 2608670, Japan
关键词
nonsmall cell lung carcinoma; endostatin; collagen XVIII; prognosis;
D O I
10.1002/cncr.20156
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. Angiogenesis plays a crucial role in tumor growth and metastasis. Recently, some studies have focused on the angiogenesis inhibitor endostatin. However, the biologic role of the precursor of endostatin, collagen XVIII, in human malignancy is unknown. The purpose of the current study was to evaluate whether the expression of collagen XVIII has additional prognostic value for survival in patients with nonsmall cell lung carcinoma (NSCLC). METHODS. The authors investigated the expression of collagen XVIII in 221 patients using immunohistochemical methods. To confirm the specificity of the collagen XVIII polyclonal antibody used in the current study and to test the expression of collagen XVIII in human lung carcinoma, Western blot analysis was performed on a panel of human lung carcinoma cell lines. RESULTS. Collagen XVIII expression was detected in 162 of 221 patients with NSCLC (73%), primarily in the tumor cell cytoplasm. Low collagen XVIII expression levels were found in 75 tumor specimens, while high collagen XVIII expression levels were noted in 87 tumor specimens. The prevalence of positive collagen XVIII expression was greater in T2-4 tumors than in T1 tumors (P = 0.0235). The prognosis for patients with strongly collagen XVIII-positive NSCLC was significantly worse than the prognosis for patients with collagen XVIII-positive or collagen XVIII-negative NSCLC (P = 0.0010). Multivariate analysis indicated that T status, lymph node status, and. the overexpression of collagen XVIII were independent prognostic factors. CONCLUSIONS. The results of the current study indicated that the overexpression of collagen XVIII was associated with NSCLC progression and poor outcome. Thus, collagen XVIII expression may serve as a useful prognostic marker in patients with NSCLC. (C) 2004 American Cancer Society.
引用
收藏
页码:1665 / 1672
页数:8
相关论文
共 55 条
[41]   Life without perlecan has its problems [J].
Olsen, BR .
JOURNAL OF CELL BIOLOGY, 1999, 147 (05) :909-911
[42]   Endostatin: An endogenous inhibitor of angiogenesis and tumor growth [J].
OReilly, MS ;
Boehm, T ;
Shing, Y ;
Fukai, N ;
Vasios, G ;
Lane, WS ;
Flynn, E ;
Birkhead, JR ;
Olsen, BR ;
Folkman, J .
CELL, 1997, 88 (02) :277-285
[43]   IDENTIFICATION OF 3 N-TERMINAL ENDS OF TYPE-XVIII COLLAGEN CHAINS AND TISSUE-SPECIFIC DIFFERENCES IN THE EXPRESSION OF THE CORRESPONDING TRANSCRIPTS - THE LONGEST FORM CONTAINS A NOVEL MOTIF HOMOLOGOUS TO RAT AND DROSOPHILA FRIZZLED PROTEINS [J].
REHN, M ;
PIHLAJANIEMI, T .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (09) :4705-4711
[44]   Complete primary structure of two variant forms of human type XVIII collagen and tissue-specific differences in the expression of the corresponding transcripts [J].
Saarela, J ;
Ylikärppä, R ;
Rehn, M ;
Purmonen, S ;
Pihlajaniemi, T .
MATRIX BIOLOGY, 1998, 16 (06) :319-328
[45]   The short and long forms of type XVIII collagen show clear tissue specificities in their expression and location in basement membrane zones in humans [J].
Saarela, J ;
Rehn, M ;
Oikarinen, A ;
Autio-Harmainen, H ;
Pihlajaniemi, T .
AMERICAN JOURNAL OF PATHOLOGY, 1998, 153 (02) :611-626
[46]   Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin [J].
Sasaki, T ;
Fukai, N ;
Mann, K ;
Göhring, W ;
Olsen, BR ;
Timpl, R .
EMBO JOURNAL, 1998, 17 (15) :4249-4256
[47]   Serum endostatin correlates with progression and prognosis of non-small cell lung cancer [J].
Suzuki, M ;
Iizasa, T ;
Ko, E ;
Baba, M ;
Saitoh, Y ;
Shibuya, K ;
Sekine, Y ;
Yoshida, S ;
Hiroshima, K ;
Fujisawa, T .
LUNG CANCER, 2002, 35 (01) :29-34
[48]  
Tanigawa N, 1996, CANCER RES, V56, P2671
[49]   Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors [J].
Thomas, JP ;
Arzoomanian, RZ ;
Alberti, D ;
Marnocha, R ;
Lee, F ;
Friedl, A ;
Tutsch, K ;
Dresen, A ;
Geiger, P ;
Pluda, J ;
Fogler, W ;
Schiller, JH ;
Wilding, G .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) :223-231
[50]  
WEIDNER N, 1995, AM J PATHOL, V147, P9